Commercial CMS molecules are the compounding engine, and the latest print shows momentum building, yet the price already assumes it all lands.
Overall read
6.3/10
Priced ahead of it
The three reads · this quarter
Commercial CMS molecules are the compounding engine, and the latest print shows momentum building, yet the price already assumes it all lands.
Overall read
6.3/10
Priced ahead of it
The three reads · this quarter
The standing reads · change less often
Moat
Moderate edge
CDMO expertise and innovator lock-in, but limited scale and customer concentration cap the moat.
Key variables
4 tracked
lead: Number of active CMS projectsStable project count, but the qualitative improvement in project size and value is a more critical signal of growth momentum.
Walk the talk
Not enough data
as of Q1 FY27Peptide manufacturing facility commissioning in Sep-2026 with strong customer interest and project visibility.
Latest · newest first
4d ago · Credit Rating
CRISIL reaffirmed LT rating at A+ and revised outlook to Positive from Stable
2w ago · Product & Approvals
Information on completion of US FDA inspection; outcome not specified.
3w ago · M&A / Investment
Execution of deed of corporate guarantee; details not provided.
3w ago · Capex & Expansion
Announced enhancement of manufacturing capacity.
13 Jul 2026 · Credit Rating
India Ratings affirmed bank loan facilities at IND A+/Positive/IND A1
1 of 1 guidance items delivered on time
Where it sits